SICOR Announces ANDA Approval for Vincristine Sulfate

Injection USP Irvine, Calif. (PROTEXT) - SICOR Inc. (Nasdaq: SCRI) todayannounced that its wholly owned subsidiary, Gensia SicorPharmaceuticals, Inc., has received approval of an AbbreviatedNew Drug Application (ANDA) from the Food and Drug Administration(FDA) for Vincristine Sulfate Injection USP, a drug indicated foracute leukemia. According to IMS, a market research firm, U.S. sales ofVincristine were approximately $5 million in 1998. The brandedproduct, Oncovin(R) Injection, is marketed by Eli Lilly andCompany. SICOR Inc. is a vertically integrated specialty pharmaceuticalcompany with proven expertise in the development, manufacturingand marketing of multi-source injectable pharmaceuticals. With astrategy of combining both the production of activepharmaceutical ingredients utilizing synthesis or fermentationand state of the art manufacturing facilities, SICOR's primaryfocus is on the worldwide injectable pharmaceutical market, whichcurrently includes oncology, anesthesiology, cardiology and othertherapeutic areas. SICOR operates several manufacturingfacilities in Europe, Mexico and the U.S.A., while maintainingits corporate headquarters in Irvine, California. This press release contains forward looking statements thatare subject to risks and uncertainties that could cause actualresults to differ materially from those set forth in the forwardlooking statements and those matters set forth in the riskfactors section of SICOR's filings on Forms 10-K and 10-Q withthe Securities and Exchange Commission. These forward lookingstatements represent the Company's judgment as of the date ofthis press release. The Company disclaims any intent orobligation to update these forward looking statements. For more information on the Company, visit SICOR's web site atwww.gensiasicor.com. News releases are also available at nocharge through PR Newswire's News On-Call fax service. For a menuof available news releases or to retrieve a specific release madeby SICOR, call 800-758-5804, extension 354050. Please retainthese numbers for future reference. ots Original Text Service:SICOR Inc. Internet: http://www.newsaktuell.de Contact: LaurieW. Little of SICOR Inc., (USA) 949-455-4879; or Carolyn Bass orJim Byers, (USA) 415-296-7383, or Patricia Walsh or EricGonzales, (USA) 212-850-5600, all of Morgen-Walke Associates,Inc., for SICOR Inc. Company News On-Call:http://www.prnewswire.com/comp/354050.html or Fax, (USA) 800-758-5804, ext. 354050 Web site: http://www.gensiasicor.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT